Concepedia

Ethan Brill

EB

Statistics

Publications

3

Citations

149

H-Index

3

Active since

2017

Affiliations

Center for Cancer Research(Current)

National Cancer Institute

Ethan Brill is an author at Center for Cancer Research specializing in pharmacology, molecular oncology, and medicine.

Publications per year

2017–2020

3

Publications

3

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer

Ethan Brill, Takuhei Yokoyama, Jayakumar R. Nair et al. · Oncotarget · 2017 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor–Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer

Tzu‐Ting Huang, Ethan Brill, Jayakumar R. Nair et al. · Cancer Research · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP

Takuhei Yokoyama, Elise C. Kohn, Ethan Brill et al. · International Journal of Oncology · 2017 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17

1–3 of 3